ArticleEuropean journal of medical research2025
Deferoxamine addresses metabolic dysregulation and urinary tract infections in weight-associated gestational diabetes mellitus.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunoinformatic Design and Evaluation of a Multi-Epitope mRNA Vaccine RP14914P Targeting Latent Tuberculosis Infection.Pathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe increasing prevalence of gestational diabetes mellitus (GDM), particularly among overweight or obese individuals, poses significant health risks. Excess iron contributes to oxidative stress, inflammation, and disruptions in immune and metabolic functions in GDM. Deferoxamine (DFO), an iron chelator, may offer a therapeutic solution by restoring immune and metabolic balance.
methodsWe conducted a comprehensive multi-omics analysis using GEO transcriptomic data, applying Weighted Gene Co-expression Network Analysis (WGCNA) and gene set enrichment analysis to identify key immune-metabolic genes. Molecular docking experiments with DFO were performed using AutoDock Vina, and interactions were visualized in PyMOL. Various in vitro assays-CCK-8, qRT-PCR, Western blot, immunofluorescence, ELISA, and colony formation tests-were conducted under high glucose conditions to assess the effects of DFO, focusing on LAMA3 and the PI3K/AKT signaling pathway.
resultsKey genes such as CDR2L, LIMCH1, LDLR, and LAMA3 were identified as being improperly regulated in cases of gestational diabetes mellitus (GDM). DFO demonstrated a significant affinity for these targets, especially LDLR. Functionally, DFO was found to improve cell survival during hyperglycemic stress, mitigate oxidative stress, and lower the concentrations of inflammatory cytokines like IL-6, IL-17, and IL-23. Notably, silencing or blocking LAMA3 reversed these effects, inhibiting the PI3K/AKT pathway, increasing apoptosis markers, and decreasing cell proliferation.
conclusionsDFO holds potential as a targeted treatment for GDM associated with obesity by addressing iron excess and immune-metabolic dysregulation. LAMA3 plays a crucial role in mediating DFO's anti-inflammatory and survival-promoting effects via the PI3K/AKT pathway. Further clinical studies are needed to explore DFO's therapeutic potential in GDM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.